Ovid Therapeutics Inc.
OVID
NASDAQ·Healthcare·Biotechnology·Mkt cap $522.6M
$2.80
▲ +0.72%
P/E
-14.00
Mkt Cap
$522.6M
52-Wk Range
$1.12–$3.11
52-Week Range
$1.12 - $3.11
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 125.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Moderate growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+16.7% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying OVID right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 13, 2026
Reported EPS of -$0.08 vs -$0.12 consensus (+30.4% surprise). Revenue of $733.0K vs $21.4K expected (+3320.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+30.4%
Revenue trend · last 2Q
—
-88%
Q1 26
Q2 26
$0
$733.0K
Margins · last 2Q
Gross
0.0%
Profit
-2047.6%
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Roth Capital · Sep 3, 2026
vs Industry
How OVID stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.